Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 162

1.

Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma.

Krayem M, Aftimos P, Najem A, van den Hooven T, van den Berg A, Hovestad-Bijl L, de Wijn R, Hilhorst R, Ruijtenbeek R, Sabbah M, Kerger J, Awada A, Journe F, Ghanem GE.

Cancers (Basel). 2020 Feb 22;12(2). pii: E512. doi: 10.3390/cancers12020512.

2.

Underreporting of alcohol use in trauma patients: A retrospective analysis.

Hoonpongsimanont W, Ghanem G, Chen Y, Sahota PK, Carroll C, Barrios C, Lotfipour S.

Subst Abus. 2019 Oct 22:1-5. doi: 10.1080/08897077.2019.1671936. [Epub ahead of print]

PMID:
31638887
3.

Immediate and long-term results of percutaneous mitral commissurotomy: up to 15 years.

Braiteh N, Zgheib A, Kashou AH, Dimassi H, Ghanem G.

Am J Cardiovasc Dis. 2019 Aug 15;9(4):34-41. eCollection 2019.

4.

The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma.

Krayem M, Sabbah M, Najem A, Wouters A, Lardon F, Simon S, Sales F, Journe F, Awada A, Ghanem GE, Van Gestel D.

Cancers (Basel). 2019 Aug 1;11(8). pii: E1093. doi: 10.3390/cancers11081093.

5.

Evaluation of prophylactic dosages of Enoxaparin in non-surgical elderly patients with renal impairment.

Chamoun N, Ghanem H, Hachem A, Hariri E, Lteif C, Mansour H, Dimassi H, Zalloum R, Ghanem G.

BMC Pharmacol Toxicol. 2019 May 7;20(1):27. doi: 10.1186/s40360-019-0308-8.

6.

Role of Macrophage Migration Inhibitory Factor (MIF) in Melanoma.

Soumoy L, Kindt N, Ghanem G, Saussez S, Journe F.

Cancers (Basel). 2019 Apr 12;11(4). pii: E529. doi: 10.3390/cancers11040529. Review.

7.

Detection of Inferior Vena Cava Thrombosis Extending into the Right Atrium Using Point-of-care Ultrasound.

Yanuck J, Ghanem G, Lahham S.

Clin Pract Cases Emerg Med. 2019 Jan 23;3(1):67-68. doi: 10.5811/cpcem.2019.1.41041. eCollection 2019 Feb. No abstract available.

8.

Assessment of bleeding in chronic liver disease and coagulopathy using the IMPROVE bleeding criteria.

Chamoun N, Ramia E, Lteif C, Salameh P, Zantout H, Ghanem G, Chatila R.

Curr Med Res Opin. 2019 Mar;35(3):427-433. doi: 10.1080/03007995.2018.1525343. Epub 2018 Oct 18.

PMID:
30221541
9.

Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma.

Krayem M, Najem A, Journe F, Morandini R, Sales F, Awada A, Ghanem GE.

Oncotarget. 2018 Aug 7;9(61):31888-31903. doi: 10.18632/oncotarget.25879. eCollection 2018 Aug 7.

10.

Targeting prohibitin with small molecules to promote melanogenesis and apoptosis in melanoma cells.

Djehal A, Krayem M, Najem A, Hammoud H, Cresteil T, Nebigil CG, Wang D, Yu P, Bentouhami E, Ghanem GE, Désaubry L.

Eur J Med Chem. 2018 Jul 15;155:880-888. doi: 10.1016/j.ejmech.2018.06.052. Epub 2018 Jun 23.

PMID:
29960207
11.

Galectins and Carcinogenesis: Their Role in Head and Neck Carcinomas and Thyroid Carcinomas.

Kindt N, Journe F, Ghanem GE, Saussez S.

Int J Mol Sci. 2017 Dec 18;18(12). pii: E2745. doi: 10.3390/ijms18122745. Review.

12.

PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies.

Perdrix A, Najem A, Saussez S, Awada A, Journe F, Ghanem G, Krayem M.

Cancers (Basel). 2017 Dec 16;9(12). pii: E172. doi: 10.3390/cancers9120172. Review.

13.

New Drug Combination Strategies in Melanoma: Current Status and Future Directions.

Najem A, Krayem M, Perdrix A, Kerger J, Awada A, Journe F, Ghanem G.

Anticancer Res. 2017 Nov;37(11):5941-5953. Review.

PMID:
29061773
14.

MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.

Zhan Y, Guo J, Yang W, Goncalves C, Rzymski T, Dreas A, Żyłkiewicz E, Mikulski M, Brzózka K, Golas A, Kong Y, Ma M, Huang F, Huor B, Guo Q, da Silva SD, Torres J, Cai Y, Topisirovic I, Su J, Bijian K, Alaoui-Jamali MA, Huang S, Journe F, Ghanem GE, Miller WH Jr, Del Rincón SV.

J Clin Invest. 2017 Nov 1;127(11):4179-4192. doi: 10.1172/JCI91258. Epub 2017 Oct 16.

15.

A non-coding function of TYRP1 mRNA promotes melanoma growth.

Gilot D, Migault M, Bachelot L, Journé F, Rogiers A, Donnou-Fournet E, Mogha A, Mouchet N, Pinel-Marie ML, Mari B, Montier T, Corre S, Gautron A, Rambow F, El Hajj P, Ben Jouira R, Tartare-Deckert S, Marine JC, Felden B, Ghanem G, Galibert MD.

Nat Cell Biol. 2017 Nov;19(11):1348-1357. doi: 10.1038/ncb3623. Epub 2017 Oct 9.

16.

N-Acetylcysteine breaks resistance to trastuzumab caused by MUC4 overexpression in human HER2 positive BC-bearing nude mice monitored by 89Zr-Trastuzumab and 18F-FDG PET imaging.

Wimana Z, Gebhart G, Guiot T, Vanderlinden B, Larsimont D, Doumont G, Van Simaeys G, Goldman S, Flamen P, Ghanem G.

Oncotarget. 2017 Apr 10;8(34):56185-56198. doi: 10.18632/oncotarget.17015. eCollection 2017 Aug 22.

17.

P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.

Najem A, Krayem M, Salès F, Hussein N, Badran B, Robert C, Awada A, Journe F, Ghanem GE.

Eur J Cancer. 2017 Sep;83:154-165. doi: 10.1016/j.ejca.2017.06.033. Epub 2017 Jul 21.

PMID:
28738256
18.

The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene.

van Kempen LC, Redpath M, Elchebly M, Klein KO, Papadakis AI, Wilmott JS, Scolyer RA, Edqvist PH, Pontén F, Schadendorf D, van Rijk AF, Michiels S, Dumay A, Helbling-Leclerc A, Dessen P, Wouters J, Stass M, Greenwood CM, Ghanem GE, van den Oord J, Feunteun J, Spatz A.

Sci Transl Med. 2016 Dec 14;8(369):369ra177.

PMID:
27974665
19.

Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience.

Musunuru HB, Yamamoto T, Klotz L, Ghanem G, Mamedov A, Sethukavalan P, Jethava V, Jain S, Zhang L, Vesprini D, Loblaw A.

J Urol. 2016 Dec;196(6):1651-1658. doi: 10.1016/j.juro.2016.06.102. Epub 2016 Aug 26.

PMID:
27569437
20.

GLI inhibitor GANT61 kills melanoma cells and acts in synergy with obatoclax.

Vlčková K, Réda J, Ondrušová L, Krayem M, Ghanem G, Vachtenheim J.

Int J Oncol. 2016 Sep;49(3):953-60. doi: 10.3892/ijo.2016.3596. Epub 2016 Jul 1.

PMID:
27572939
21.

Diagnosis, referral, and primary treatment decisions in newly diagnosed prostate cancer patients in a multidisciplinary diagnostic assessment program.

Guy D, Ghanem G, Loblaw A, Buckley R, Persaud B, Cheung P, Chung H, Danjoux C, Morton G, Noakes J, Spevack L, Hajek D, Flax S.

Can Urol Assoc J. 2016 Mar-Apr;10(3-4):120-5. doi: 10.5489/cuaj.3510.

22.

The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters.

Brouwers B, Hatse S, Dal Lago L, Neven P, Vuylsteke P, Dalmasso B, Debrock G, Van Den Bulck H, Smeets A, Bechter O, Bailur JK, Kenis C, Laenen A, Schöffski P, Pawelec G, Journe F, Ghanem GE, Wildiers H.

Oncotarget. 2016 May 24;7(21):29977-88. doi: 10.18632/oncotarget.8796.

23.

p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.

Krayem M, Journe F, Wiedig M, Morandini R, Najem A, Salès F, van Kempen LC, Sibille C, Awada A, Marine JC, Ghanem G.

Eur J Cancer. 2016 Mar;55:98-110. doi: 10.1016/j.ejca.2015.12.002. Epub 2016 Jan 17.

PMID:
26790143
24.

Metastatic Prostate Cancer in Men Initially Treated with Active Surveillance.

Yamamoto T, Musunuru HB, Vesprini D, Zhang L, Ghanem G, Loblaw A, Klotz L.

J Urol. 2016 May;195(5):1409-1414. doi: 10.1016/j.juro.2015.11.075. Epub 2015 Dec 18.

PMID:
26707510
25.

Spinal versus general anesthesia for Cesarean section in patients with sickle cell anemia.

Bakri MH, Ismail EA, Ghanem G, Shokry M.

Korean J Anesthesiol. 2015 Oct;68(5):469-75. doi: 10.4097/kjae.2015.68.5.469. Epub 2015 Sep 30.

26.

Melanins and melanogenesis: from pigment cells to human health and technological applications.

d'Ischia M, Wakamatsu K, Cicoira F, Di Mauro E, Garcia-Borron JC, Commo S, Galván I, Ghanem G, Kenzo K, Meredith P, Pezzella A, Santato C, Sarna T, Simon JD, Zecca L, Zucca FA, Napolitano A, Ito S.

Pigment Cell Melanoma Res. 2015 Sep;28(5):520-44. doi: 10.1111/pcmr.12393. Review.

PMID:
26176788
27.

SNPs at miR-155 binding sites of TYRP1 explain discrepancy between mRNA and protein and refine TYRP1 prognostic value in melanoma.

El Hajj P, Gilot D, Migault M, Theunis A, van Kempen LC, Salés F, Fayyad-Kazan H, Badran B, Larsimont D, Awada A, Bachelot L, Galibert MD, Ghanem G, Journe F.

Br J Cancer. 2015 Jun 30;113(1):91-8. doi: 10.1038/bjc.2015.194. Epub 2015 Jun 11.

28.

Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state.

Verfaillie A, Imrichova H, Atak ZK, Dewaele M, Rambow F, Hulselmans G, Christiaens V, Svetlichnyy D, Luciani F, Van den Mooter L, Claerhout S, Fiers M, Journe F, Ghanem GE, Herrmann C, Halder G, Marine JC, Aerts S.

Nat Commun. 2015 Apr 9;6:6683. doi: 10.1038/ncomms7683.

29.

Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.

Muylle K, Flamen P, Vugts DJ, Guiot T, Ghanem G, Meuleman N, Bourgeois P, Vanderlinden B, van Dongen GA, Everaert H, Vaes M, Bron D.

Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1304-14. doi: 10.1007/s00259-015-3025-6. Epub 2015 Mar 20.

30.

Survey on skin-lightening practices and cosmetics in Kigali, Rwanda.

Kamagaju L, Morandini R, Gahongayire F, Stévigny C, Ghanem G, Pirotte G, Duez P.

Int J Dermatol. 2016 Jan;55(1):45-51. doi: 10.1111/ijd.12833. Epub 2015 Mar 13.

PMID:
25773999
31.

Mucolytic Agents Can Enhance HER2 Receptor Accessibility for [(89)Zr]Trastuzumab, Improving HER2 Imaging in a Mucin-Overexpressing Breast Cancer Xenograft Mouse Model.

Wimana Z, Gebhart G, Guiot T, Vanderlinden B, Morandini R, Doumont G, Sherer F, Van Simaeys G, Goldman S, Ghanem G, Flamen P.

Mol Imaging Biol. 2015 Oct;17(5):697-703. doi: 10.1007/s11307-015-0840-x.

PMID:
25761907
32.

Achieving low-density lipoprotein cholesterol treatment goals among dyslipidemic individuals in the Levant: the CEntralized Pan-Levant survey on tHE Undertreatment of hypercholeSterolemia (CEPHEUS) study.

Hammoudeh AJ, Echtay A, Ghanem GY, Haddad J; CEPHEUS-Levant survey investigators.

Curr Med Res Opin. 2014 Oct;30(10):1957-65. doi: 10.1185/03007995.2014.929095. Epub 2014 Jun 18.

PMID:
24889279
33.

Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression.

Denecker G, Vandamme N, Akay O, Koludrovic D, Taminau J, Lemeire K, Gheldof A, De Craene B, Van Gele M, Brochez L, Udupi GM, Rafferty M, Balint B, Gallagher WM, Ghanem G, Huylebroeck D, Haigh J, van den Oord J, Larue L, Davidson I, Marine JC, Berx G.

Cell Death Differ. 2014 Aug;21(8):1250-61. doi: 10.1038/cdd.2014.44. Epub 2014 Apr 25.

34.

Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib.

Krayem M, Journe F, Wiedig M, Morandini R, Sales F, Awada A, Ghanem G.

Eur J Cancer. 2014 May;50(7):1310-20. doi: 10.1016/j.ejca.2014.01.021. Epub 2014 Feb 19.

PMID:
24559688
35.

Influence of paramagnetic melanin on the MRI contrast in melanoma: a combined high-field (11.7 T) MRI and EPR study.

Godechal Q, Mignion L, Karroum O, Magat J, Danhier P, Morandini R, Ghanem GE, Leveque P, Gallez B.

Contrast Media Mol Imaging. 2014 Mar-Apr;9(2):154-60. doi: 10.1002/cmmi.1554.

36.

HER4 and its cytoplasmic isoforms are associated with progression-free survival of malignant melanoma.

Nielsen TO, Poulsen SS, Journe F, Ghanem G, Sorensen BS.

Melanoma Res. 2014 Feb;24(1):88-91. doi: 10.1097/CMR.0000000000000040.

PMID:
24366194
37.

An ethnobotanical survey of medicinal plants used in Rwanda for voluntary depigmentation.

Kamagaju L, Bizuru E, Minani V, Morandini R, Stévigny C, Ghanem G, Duez P.

J Ethnopharmacol. 2013 Nov 25;150(2):708-17. doi: 10.1016/j.jep.2013.09.031. Epub 2013 Oct 3.

PMID:
24095698
38.

Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: a rationale to combine targeted drugs based on protein expression inhibition profiles.

Aftimos PG, Wiedig M, Langouo Fontsa M, Awada A, Ghanem G, Journe F.

Int J Oncol. 2013 Sep;43(3):919-26. doi: 10.3892/ijo.2013.2008. Epub 2013 Jul 8.

PMID:
23835698
39.

Pharmacological inhibition of macrophage migration inhibitory factor interferes with the proliferation and invasiveness of squamous carcinoma cells.

Kindt N, Laurent G, Nonclercq D, Journé F, Ghanem G, Duvillier H, Gabius HJ, Lechien J, Saussez S.

Int J Oncol. 2013 Jul;43(1):185-93. doi: 10.3892/ijo.2013.1944. Epub 2013 May 16.

PMID:
23677331
40.
41.

Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients.

El Hajj P, Journe F, Wiedig M, Laios I, Salès F, Galibert MD, Van Kempen LC, Spatz A, Badran B, Larsimont D, Awada A, Ghanem G.

Br J Cancer. 2013 Apr 30;108(8):1641-7. doi: 10.1038/bjc.2013.115. Epub 2013 Mar 21.

42.

Tyrosinase modulation by five Rwandese herbal medicines traditionally used for skin treatment.

Kamagaju L, Morandini R, Bizuru E, Nyetera P, Nduwayezu JB, Stévigny C, Ghanem G, Duez P.

J Ethnopharmacol. 2013 Apr 19;146(3):824-34. doi: 10.1016/j.jep.2013.02.010. Epub 2013 Feb 22.

PMID:
23439030
43.

Functional status and relationships of melanocortin 1 receptor signaling to the cAMP and extracellular signal-regulated protein kinases 1 and 2 pathways in human melanoma cells.

Herraiz C, Journé F, Ghanem G, Jiménez-Cervantes C, García-Borrón JC.

Int J Biochem Cell Biol. 2012 Dec;44(12):2244-52. doi: 10.1016/j.biocel.2012.09.008. Epub 2012 Sep 19.

PMID:
23000456
44.

MDM4 is a key therapeutic target in cutaneous melanoma.

Gembarska A, Luciani F, Fedele C, Russell EA, Dewaele M, Villar S, Zwolinska A, Haupt S, de Lange J, Yip D, Goydos J, Haigh JJ, Haupt Y, Larue L, Jochemsen A, Shi H, Moriceau G, Lo RS, Ghanem G, Shackleton M, Bernal F, Marine JC.

Nat Med. 2012 Aug;18(8):1239-47. doi: 10.1038/nm.2863. Epub 2012 Jul 22.

45.

Breast cancer suppressor candidate-1 (BCSC-1) is a melanoma tumor suppressor that down regulates MITF.

Anghel SI, Correa-Rocha R, Budinska E, Boligan KF, Abraham S, Colombetti S, Fontao L, Mariotti A, Rimoldi D, Ghanem GE, Fisher DE, Lévy F, Delorenzi M, Piguet V.

Pigment Cell Melanoma Res. 2012 Jul;25(4):482-7. doi: 10.1111/j.1755-148X.2012.01018.x. Erratum in: Pigment Cell Melanoma Res. 2012 Nov;25(6):834. Correa-Rochal, Rafael [corrected to Correa-Rocha, Rafael]; Boliganl, Kayluz F [corrected to Boligan, Kayluz F].

PMID:
22594792
46.

Has removal of excess cysteine led to the evolution of pheomelanin? Pheomelanogenesis as an excretory mechanism for cysteine.

Galván I, Ghanem G, Møller AP.

Bioessays. 2012 Jul;34(7):565-8. doi: 10.1002/bies.201200017. Epub 2012 Mar 22.

PMID:
22442057
47.

[Survey concerning exposure of staff to UV radiation at four Brussels hospitals].

Lam Hoai XL, André J, Del Marmol V, Ghanem GE, Salès F, Vereecken P.

Ann Dermatol Venereol. 2012 Feb;139(2):91-102. doi: 10.1016/j.annder.2011.10.412. Epub 2012 Jan 20. French.

PMID:
22325747
48.

TYRP1 mRNA expression in melanoma metastases correlates with clinical outcome.

Journe F, Id Boufker H, Van Kempen L, Galibert MD, Wiedig M, Salès F, Theunis A, Nonclercq D, Frau A, Laurent G, Awada A, Ghanem G.

Br J Cancer. 2011 Nov 22;105(11):1726-32. doi: 10.1038/bjc.2011.451. Epub 2011 Nov 1.

49.

Role of farnesoid X receptor (FXR) in the process of differentiation of bone marrow stromal cells into osteoblasts.

Id Boufker H, Lagneaux L, Fayyad-Kazan H, Badran B, Najar M, Wiedig M, Ghanem G, Laurent G, Body JJ, Journé F.

Bone. 2011 Dec;49(6):1219-31. doi: 10.1016/j.bone.2011.08.013. Epub 2011 Aug 26.

PMID:
21893226
50.

Tyrosinase related protein 1 (TYRP1/gp75) in human cutaneous melanoma.

Ghanem G, Fabrice J.

Mol Oncol. 2011 Apr;5(2):150-5. doi: 10.1016/j.molonc.2011.01.006. Epub 2011 Feb 3. Review.

Supplemental Content

Loading ...
Support Center